abacavir + didanosine + lopinavir + ritonavir

This is a combination antiretroviral regimen consisting of four drugs—abacavir, didanosine, lopinavir, and ritonavir—used in the treatment of human immunodeficiency virus (HIV) infection. Each component has a distinct mechanism of action targeting different stages of the HIV life cycle: - Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by causing DNA chain termination. - Didanosine is also an NRTI with similar action to abacavir. - Lopinavir is an HIV-1 protease inhibitor that prevents viral polyprotein cleavage, resulting in immature, non-infectious viral particles. - Ritonavir acts primarily as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A-mediated metabolism of lopinavir, thereby increasing its plasma concentration and antiviral efficacy. This combination targets both reverse transcription and proteolytic processing steps essential for HIV replication. The regimen may be used in patients with HIV infection to reduce viral load and delay disease progression. These drugs are not curative but can significantly improve immune function and reduce the risk of AIDS-related complications when used together[2][5][6].

Other names

didanosine/abacavir/lopinavir-ritonavirddI + ABC + LPV/rdidanosine + abacavir + lopinavir-ritonavir